Covance, Inc. has entered into an agreement to acquire the eight early phase clinical development sites of Radiant Research, Inc. for approximately $65 million. “This acquisition will give Covance a significant expansion of clinical pharmacology bed capacity and broaden our access to special patient populations for Phase Ib/IIa clinical studies,” said Joe Herring, Covance chairman and chief executive officer. “Early phase clinical trials continue to be one of the biggest b...